NextFin News - Shares of AstraZeneca fell 2.44% in London trading on Friday after a U.S. Food and Drug Administration (FDA) advisory panel voted against the approval of camizestrant, an experimental oral drug for breast cancer. The Oncologic Drugs Advisory Committee (ODAC) voted 6-3 late Thursday that the benefit-risk profile of the drug had not been sufficiently established, specifically questioning the design of the SERENA-6 Phase III trial. The stock was trading at 13,608.00 pence following the news, reflecting investor caution over a drug once seen as a potential pillar of the company’s oncology portfolio.
The regulatory setback centers on AstraZeneca’s proposal to switch patients to camizestrant as soon as an ESR1 mutation is detected, rather than waiting for radiographic evidence of disease progression. While the SERENA-6 trial demonstrated a 56% reduction in the risk of disease progression or death compared to standard care, the FDA panel expressed skepticism regarding whether this early intervention translates into long-term survival benefits. Panel members noted that the trial design did not adequately compare the early-switch strategy against the current standard of waiting for progression before changing therapies, suggesting the approach might introduce unknown risks by accelerating the treatment sequence.
James Gordon, an analyst at Barclays, noted that the debate remains nuanced despite the negative vote. Gordon, who has historically maintained a balanced view on the pharmaceutical giant, argued that the panel did not dismiss the drug’s efficacy or safety but rather the specific clinical practice shift proposed by the trial. He suggested that the outcome is more of a regulatory hurdle than a terminal failure for the molecule. This perspective is not yet a consensus view, as some market participants fear the FDA’s likely rejection could delay camizestrant’s market entry by years, allowing competitors to solidify their positions in the lucrative breast cancer market.
The financial impact of the vote may be contained within the broader context of AstraZeneca’s ambitious growth strategy. Analysts at Jefferies pointed out that camizestrant was only a minor component of the company’s stated goal to reach $80 billion in annual sales by 2030. They characterized the current share price weakness as a "sentiment hit" rather than a fundamental breakdown of the investment thesis. AstraZeneca has enjoyed a strong run over the past year, with its stock rising approximately 25% and outperforming the FTSE 100 index, driven by a series of positive data readouts in lung cancer and other oncology indications.
AstraZeneca’s Executive Vice President of Oncology R&D, Susan Galbraith, stated that the company remains committed to the drug and will continue to work with the FDA during the remainder of the review process. While the FDA is not legally bound by the advisory committee’s recommendation, it typically follows the panel’s lead. The company still has 11 major clinical trial readouts expected throughout the remainder of 2026, which may provide the necessary catalysts to offset the camizestrant disappointment. For now, the focus shifts to whether the company can provide additional data to satisfy regulators or if it will be forced to conduct new, more traditional trials to prove long-term clinical benefit.
Explore more exclusive insights at nextfin.ai.
